Jason Vilar highlights updates in the management of status epilepticus before focusing on refractory and super refractory status epilepticus in Part II of this episode series.

Status Epilepticus: Part II features Neurocritical Pharmacist Jason Vilar, highlighting status epilepticus (SE) treatment updates since Part I (an episode featuring Karen Berger) before shifting our focus to refractory (RSE) and super refractory SE (SRSE). What are risk factors? How do we identify or define RSE and SRSE? Is there a preferred terminology when referencing SE pharmacotherapy? Jason and I each pick 2 trials to create the “Mt Rushmore” of Status Epilepticus landmark literature.

Then our discussion moves to pharmacotherapy. How does home medication use affect agent selection? Advice on managing DDI? Should we use TDM? Which agents can we give fastest, via IVP? How does our continuous IV sedative dosing differ when used in SE? Are there general medication principles to keep in mind? How can we wean off these agents? Literature on the horizon? And much, much more!

Previous episodes related to Status Epilepticus: Part II